Cargando…

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia

BACKGROUND: Fludarabine, is one of the most active single agents in the treatment of chronic lymphocytic leukemia (CLL). Over time, however, virtually all CLL patients become fludarabine-refractory. To elucidate whether microRNAs are involved in the development of fludarabine resistance, we analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferracin, Manuela, Zagatti, Barbara, Rizzotto, Lara, Cavazzini, Francesco, Veronese, Angelo, Ciccone, Maria, Saccenti, Elena, Lupini, Laura, Grilli, Andrea, De Angeli, Cristiano, Negrini, Massimo, Cuneo, Antonio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892453/
https://www.ncbi.nlm.nih.gov/pubmed/20504344
http://dx.doi.org/10.1186/1476-4598-9-123
_version_ 1782182947614359552
author Ferracin, Manuela
Zagatti, Barbara
Rizzotto, Lara
Cavazzini, Francesco
Veronese, Angelo
Ciccone, Maria
Saccenti, Elena
Lupini, Laura
Grilli, Andrea
De Angeli, Cristiano
Negrini, Massimo
Cuneo, Antonio
author_facet Ferracin, Manuela
Zagatti, Barbara
Rizzotto, Lara
Cavazzini, Francesco
Veronese, Angelo
Ciccone, Maria
Saccenti, Elena
Lupini, Laura
Grilli, Andrea
De Angeli, Cristiano
Negrini, Massimo
Cuneo, Antonio
author_sort Ferracin, Manuela
collection PubMed
description BACKGROUND: Fludarabine, is one of the most active single agents in the treatment of chronic lymphocytic leukemia (CLL). Over time, however, virtually all CLL patients become fludarabine-refractory. To elucidate whether microRNAs are involved in the development of fludarabine resistance, we analyzed the expression of 723 human miRNAs before and 5-days after fludarabine mono-therapy in 17 CLL patients which were classified as responder or refractory to fludarabine treatment based on NCI criteria. RESULTS: By comparing the expression profiles of these two groups of patients, we identified a microRNA signature able to distinguish refractory from sensitive CLLs. The expression of some microRNAs was also able to predict fludarabine resistance of 12 independent CLL patients. Among the identified microRNAs, miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients either before and after fludarabine treatment. After performing messenger RNA expression profile of the same patients, the activation of p53-responsive genes was detected in fludarabine responsive cases only, therefore suggesting a possible mechanism linked to microRNA deregulation in non-responder patients. Importantly, inhibition of miR-21 and miR-222 by anti-miRNA oligonucleotides induced a significant increase in caspase activity in fludarabine-treated p53-mutant MEG-01 cells, suggesting that miR-21 and miR-222 up-regulation may be involved in the establishment of fludarabine resistance. CONCLUSIONS: This is the first report that reveals the existence of a microRNA profile that differentiate refractory and sensitive CLLs, either before and after fludarabine mono-therapy. A p53 dysfunctional pathway emerged in refractory CLLs and could contribute in explaining the observed miRNA profile. Moreover, this work indicates that specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets, therefore establishing an important starting point for future studies.
format Text
id pubmed-2892453
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28924532010-06-26 MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia Ferracin, Manuela Zagatti, Barbara Rizzotto, Lara Cavazzini, Francesco Veronese, Angelo Ciccone, Maria Saccenti, Elena Lupini, Laura Grilli, Andrea De Angeli, Cristiano Negrini, Massimo Cuneo, Antonio Mol Cancer Research BACKGROUND: Fludarabine, is one of the most active single agents in the treatment of chronic lymphocytic leukemia (CLL). Over time, however, virtually all CLL patients become fludarabine-refractory. To elucidate whether microRNAs are involved in the development of fludarabine resistance, we analyzed the expression of 723 human miRNAs before and 5-days after fludarabine mono-therapy in 17 CLL patients which were classified as responder or refractory to fludarabine treatment based on NCI criteria. RESULTS: By comparing the expression profiles of these two groups of patients, we identified a microRNA signature able to distinguish refractory from sensitive CLLs. The expression of some microRNAs was also able to predict fludarabine resistance of 12 independent CLL patients. Among the identified microRNAs, miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients either before and after fludarabine treatment. After performing messenger RNA expression profile of the same patients, the activation of p53-responsive genes was detected in fludarabine responsive cases only, therefore suggesting a possible mechanism linked to microRNA deregulation in non-responder patients. Importantly, inhibition of miR-21 and miR-222 by anti-miRNA oligonucleotides induced a significant increase in caspase activity in fludarabine-treated p53-mutant MEG-01 cells, suggesting that miR-21 and miR-222 up-regulation may be involved in the establishment of fludarabine resistance. CONCLUSIONS: This is the first report that reveals the existence of a microRNA profile that differentiate refractory and sensitive CLLs, either before and after fludarabine mono-therapy. A p53 dysfunctional pathway emerged in refractory CLLs and could contribute in explaining the observed miRNA profile. Moreover, this work indicates that specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets, therefore establishing an important starting point for future studies. BioMed Central 2010-05-26 /pmc/articles/PMC2892453/ /pubmed/20504344 http://dx.doi.org/10.1186/1476-4598-9-123 Text en Copyright ©2010 Ferracin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ferracin, Manuela
Zagatti, Barbara
Rizzotto, Lara
Cavazzini, Francesco
Veronese, Angelo
Ciccone, Maria
Saccenti, Elena
Lupini, Laura
Grilli, Andrea
De Angeli, Cristiano
Negrini, Massimo
Cuneo, Antonio
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title_full MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title_fullStr MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title_full_unstemmed MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title_short MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
title_sort micrornas involvement in fludarabine refractory chronic lymphocytic leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892453/
https://www.ncbi.nlm.nih.gov/pubmed/20504344
http://dx.doi.org/10.1186/1476-4598-9-123
work_keys_str_mv AT ferracinmanuela micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT zagattibarbara micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT rizzottolara micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT cavazzinifrancesco micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT veroneseangelo micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT cicconemaria micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT saccentielena micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT lupinilaura micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT grilliandrea micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT deangelicristiano micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT negrinimassimo micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia
AT cuneoantonio micrornasinvolvementinfludarabinerefractorychroniclymphocyticleukemia